Researchers Database

okazaki hitoaki

    Medical Education Center Professor
Last Updated :2022/11/26

Researcher Information

Degree

  • (BLANK)(Jichi Medical University)

J-Global ID

Research Interests

  • 医学教育学   総合診療   臨床免疫学   アレルギ-膠原病学   Medical Education   Clinical Immunology   Allergology & Rheumatology   

Research Areas

  • Life sciences / Allergies and connective tissue disease
  • Life sciences / Internal medicine - General
  • Life sciences / Immunology

Education

  •        - 1992  Jichi Medical University  医学研究科  結合織疾患
  •        - 1992  Jichi Medical University  Graduate School, Division of Medicine
  •        - 1984  Jichi Medical University  医学部
  •        - 1984  Jichi Medical University  Faculty of Medicine

Association Memberships

  • American College of Physiclans(ACP)   日本内科専門医会   アメリカリウマチ学会   日本臨床免疫学会   日本リウマチ学会   日本アレルギ-学会   日本免疫学会   日本内科学会   

Books etc

  • リウマチ、膠原病(共著)
    ()
    疾患からみた臨床薬理学 薬業時報社 1999

MISC

  • N Umemoto, M Kakurai, H Okazaki, T Kiyosawa, T Demitsu, H Nakagawa  JOURNAL OF DERMATOLOGICAL SCIENCE  31-  (2)  161  -164  2003/04  [Not refereed][Not invited]
     
    Vasoactive intestinal peptide (VIP) has been suggested to play some roles in atopic dermatitis. Tissue of VIP levels has been reported to increase in chronic lichenified lesions of atopic dermatitis (AD). To analyze whether serum levels of VIP in AD patients are elevated compared with normal controls and correlated with the disease severity, we measured serum levels of VIP using enzyme-linked immunosorbent assay in 53 patients with AD and 21 healthy individuals. The results showed that serum levels of VIP in AD patients (345.8 +/- 71.5 mug/ml) were significantly higher than those in healthy individuals (307.1 +/- 42.6 mug/ml). However, a correlation was not found between serum VIP levels and disease severity, other markers including serum LDH levels, total serum IgE levels, and peripheral blood eosinophil counts in patients with AD. This indicates that VIP levels in AD patients were elevated not only in the skin but also in the serum, suggesting that increased serum VIP levels in the patients with AD might be involved in its pathogenesis. (C) 2003 Elsevier Science Ireland Ltd. and the Japanese Society of Investigative Dermatology. All rights reserved.
  • N Umemoto, M Kakurai, H Okazaki, T Kiyosawa, T Demitsu, H Nakagawa  JOURNAL OF DERMATOLOGICAL SCIENCE  31-  (2)  161  -164  2003/04  [Not refereed][Not invited]
     
    Vasoactive intestinal peptide (VIP) has been suggested to play some roles in atopic dermatitis. Tissue of VIP levels has been reported to increase in chronic lichenified lesions of atopic dermatitis (AD). To analyze whether serum levels of VIP in AD patients are elevated compared with normal controls and correlated with the disease severity, we measured serum levels of VIP using enzyme-linked immunosorbent assay in 53 patients with AD and 21 healthy individuals. The results showed that serum levels of VIP in AD patients (345.8 +/- 71.5 mug/ml) were significantly higher than those in healthy individuals (307.1 +/- 42.6 mug/ml). However, a correlation was not found between serum VIP levels and disease severity, other markers including serum LDH levels, total serum IgE levels, and peripheral blood eosinophil counts in patients with AD. This indicates that VIP levels in AD patients were elevated not only in the skin but also in the serum, suggesting that increased serum VIP levels in the patients with AD might be involved in its pathogenesis. (C) 2003 Elsevier Science Ireland Ltd. and the Japanese Society of Investigative Dermatology. All rights reserved.
  • アレルギー・リウマチ・膠原病における免疫抑制剤の使い方
    内科専門医会誌  15, 254-259-  2003  [Not refereed][Not invited]
  • Ann Rheum Dis  61, 761-762-  2002  [Not refereed][Not invited]
  • Characterization of chemokire receptor expression and eytokire production in ciroulstirg CD4+T cells from patients with atopic dermatits
    Clin Exp Allergy  32, 1236-1242-  2002  [Not refereed][Not invited]
  • Effects of FTY720 in MRL-lpr/lpr Mice:Therapeutic Protential in Systemic Lupus Erythematosus
    J Rheumato 1  29, 707-716-  2002  [Not refereed][Not invited]
  • 免疫抑制剤(FTY720)
    臨床免疫  38[Suppl. 20], 67-72-  2002  [Not refereed][Not invited]
  • 老人病と補体
    六法出版 老人病診療Q & A  38-  1034  -1037  2002  [Not refereed][Not invited]
  • スタチンの免疫抑制作用
    最新医学社  57(6), 125-128-  2002  [Not refereed][Not invited]
  • Ann Rheum Dis  61, 761-762-  2002  [Not refereed][Not invited]
  • Characterization of chemokire receptor expression and eytokire production in ciroulstirg CD4+T cells from patients with atopic dermatitis
    Clin Exp Allergy  32, 1236-1242-  2002  [Not refereed][Not invited]
  • Effects of FTY720 in MRL-lpr/lpr Mice:Therapeutic Protential in Systemic Lupus Erythematosus
    J Rheumato 1  29, 707-716-  2002  [Not refereed][Not invited]
  • K Kuroiwa, T Arai, H Okazaki, S Minota, S Tominaga  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS  284-  (5)  1104  -1108  2001/06  [Not refereed][Not invited]
     
    Soluble human ST2 protein (IL1RL1-a) in the sera of patients with various autoimmune diseases was identified by a newly developed procedure using specific monoclonal antibodies. After immunoprecipitation and subsequent immunoblotting, a glycosylated protein of about 60 kDa was detected in the sera of SLE patients, but not in the sera of healthy controls. The experiments using gel filtration and SDS-PAG;E under a nonreducing condition indicated the existence of the ST2 multimer in serum. The mobility of the natural protein was slower than that of the recombinant human ST2 protein produced by COS7 cells in SDS-PAGE, suggesting a difference of glycosylation between humans and monkeys. The identification of the natural human ST2 protein should be important both to fundamental researches and the further clarification of the clinical implications of the ST2 protein. (C) 2001 Academic Press.
  • 発熱と頭痛とを呈し、精査加療目的で入院した30歳の男性
    内科専門医会誌  12-  (4)  674  -690  2000  [Not refereed][Not invited]
  • くも膜下出血と全身性エリテマトーデス
    ループス  9-  521  -526  2000  [Not refereed][Not invited]
  • KANEKO Naoko, MIMORI Akio, BABA Satoshi, NARA Hiroyuki, SHIROTA Yuko, NAGASHIMA Takao, HIRATA Daisuke, YOSHIO Taku, OKAZAKI Hitoaki, KANO Shogo, MINOTA Seiji  リウマチ  40-  (3)  633  -638  2000  [Not refereed][Not invited]
  • T細胞補助受容体分子ICOSの同定とその意義
    臨床免疫  33-  (1)  119  2000  [Not refereed][Not invited]
  • Drclofenac-induced aseptic meningitis
    12-  (4)  674  -690  2000  [Not refereed][Not invited]
  • A Mimori, T Suzuki, M Hashimoto, H Nara, T Yoshio, JI Masuyama, H Okazaki, D Hirata, S Kano, S Minota  LUPUS  9-  (7)  521  -526  2000  [Not refereed][Not invited]
     
    The frequency, clinical profile, treatment and outcome of subarachnoid hemorrhage (SAH) in patients with systemic lupus erythematosus (SLE) were assessed retrospectively, based on the case records of SLE of the Jichi Medical School Hospital over a 20 year period. Clinically defined SAH was found in 10 (3.9%) out of 258 SLE patients, which represented a frequency higher than previously assumed. Five patients had active SLE and lacked an apparent cause of SAH, other than SLE. A high mortality rate (5/5), no visible aneurysm on angiogram (3/4), and an onset during intractable SLE or after discontinued or no steroid therapy because of medical noncompliance (4/5) were characteristic of patients with active SLE, and thus an earlier successful suppression of SLE, if possible, might have plt vented their SAH. In contrast, in the 5 patients with inactive SLE, 2 out of 3 saccular aneurysms were succcessfuly clipped and small bleeding of one patient without aneurysms remitted spontaneously without the need for additional steroid therapy. When one death, which occurred outside of medical care, was excluded, the survival ratio of the hospitalized SAH patients with inactive SLE was significantly better than that with active SLE (3/4 versus 0/5, P = 0.0476). In conclusion, the relatively common occurence of SAH in SLE patients, and a significantly different clinical impact of SAH in respect to active and inactive SLE, were suggested from the results.
  • Rapidly Progressed Secondary Amyloidosis in a Patient with Still's Disease with α-allele in His SAA1 Gene
    Rhiemachi  40-  (3)  633  -638  2000  [Not refereed][Not invited]
  • In vitro and in vivo inhibition of activation induced T cell apoptosis by bucillamine.
    J. Rheumatol  27-  (6)  1358  2000  [Not refereed][Not invited]
  • ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
    33-  (1)  119  2000  [Not refereed][Not invited]
  • Sj(]E88D8[)gren症候群に伴う髄膜炎,髄膜脳炎
    神経内科  51-  140  1999  [Not refereed][Not invited]
  • Weber-Christian病
    外来診療のすべて(改訂第2版)Medical View  804  -805  1999  [Not refereed][Not invited]
  • 体温の上昇(高体温と発熱)
    外来診療のすべて(改訂第2版)Medical View  46  -49  1999  [Not refereed][Not invited]
  • 副刺激ブロックによる全身性エリテマトーデスの治療
    内科  83-  123  -126  1999  [Not refereed][Not invited]
  • Meningitis(meningoencephalitis) in sj(]E88D8[)gren syndrone
    51-  140  1999  [Not refereed][Not invited]
  • Early diagnosis of Takayasu arteritis using gadolinium-enhanced magnetic resonance
    Arthritis & Rheunotism  42-  (7)  1549  1999  [Not refereed][Not invited]
  • Infection with an Unenvelaped DNA virus(TTV)Associated with Non A to G Hepatitis in Patients With Rheumatoid Arthritis
    British Journal of Rheumatology  37-  (12)  1361  1998  [Not refereed][Not invited]
  • Therapeutic effects of C2-ceramide and FTY720 on the clinical course of MRL-lpr/lpr mice.
    Arthritis. Rheum.  (41)  S175  1998  [Not refereed][Not invited]
  • Nucleolin as one of the earliest targets of autoantibodies produced in NZB/W F1 and NRL/lpr lupus-prone mice.
    Arthritis. Rheum.  (41)  S254  1998  [Not refereed][Not invited]
  • Correlation of serum IgG artibodies to recombinant PO fusion protein with IgG antibodies to carboxylterminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-deleted recombinant PO fusion protein in patients with ststemic lupus erythematosus
    Arthritis Rheum.  (40)  1364  1997  [Not refereed][Not invited]
  • J. Exp. Med.  181-  (6)  2201  -2211  1995  [Not refereed][Not invited]
  • 肺高血圧症を伴ったSLEの1剖検例。
    33-  540  1994  [Not refereed][Not invited]
  • Masaki SATO, Hitoaki OKAZAKI, Hiroshi OKAMOTO, Akihiko OHTAKA, Hideo SHIMIZU, Nagahiro MINATO, Shogo KANO  Jpn. J. Med  33-  (9)  540  -542  1994  [Not refereed][Not invited]
  • CD3+4-8-αβ cell population with biased T-cell receptor Vβ gene usage. Presence in bone marrow and possible involvement of IL-3 for their extrathymic development
    J. Immunol.  149-  1143  1992  [Not refereed][Not invited]
  • Yasuki Ogawa, Hitoaki Okazaki, Tetsuo Sudo, Noriko Ohno, Masayo Itoh, Masakazu Hattori, Masahiko Lizuka, Nagahiro Minato  International Immunology  3-  (1)  39  -47  1991/01  [Not refereed][Not invited]
     
    Interleukin 2 (IL-2)-dependent granular T lymphocyte (GTL) lines derived from murlne spleen were shown to express a Ly-5 antigen with the so-called 'B220-epltope' recognized by 6B2 mAbs, which were normally exhibited on B-lineage cells. Immunoprecipitatlon analysis revealed that the Ly-5 isoform on GTL lines represented the highest-molecular-weight Ly-5 so far described (260 kd), distinct from the B220 isoform on a pre-B cell line (240 kd). The size difference between them was also evident after the endoglycosidase treatment (210 versus 190 kd), strongly suggesting that these Ly-5 isoforms had core proteins of distinct size. Sequential immunoprecipitation by 6B2 and 14.8 mAbs further indicated that the 260 kd Ly-5 on GTL lines predominantly expressed '6B2 epitope' while '14.8 epitope' dominated In the B220 (240 kd) on a pre-B cell line. Northern blot analysis of the Ly-5 transcripts using probes for the known alternative exons failed to show any evidence for mRNA of the 260 kd Ly-5 distinct from that of B220. Polymerase chain reaction analysis, however, suggested that the 260 kd Isoform mRNA might be transcribed from a distinct promoter with a yet undefined exon(s). The 6B2+ Ly-5 isoform was hardly detected on normal splenic T cells, but was shown to be induced rapidly on the majority of T cells following IL-2 stimulation in vitro, indicating that this particular Ly-5 isoform behaved as an 'activation antigen' on T cells. In contrast, splenic B cells constitutively expressed 6B2+ Ly-5, although the mol. wt was quite different between the primary B cells and LPS-activated B cells. The unique nature of the 6B2 epitope expressed on the selected Ly-5 isoforms is also discussed. © 1991 Oxford University Press.
  • M HATTORI, H OKAZAKI, Y ISHIDA, M ONUMA, S KANO, T HONJO, N MINATO  JOURNAL OF IMMUNOLOGY  144-  (10)  3809  -3815  1990/05  [Not refereed][Not invited]
  • Effect of various interleukins on human B cell activation : Analysis of inhibitory action of IL-4
    Allergy & Immunology  9-  165  1990  [Not refereed][Not invited]
  • Identification and gene cloning of a new phosphatidylirositol-linked antigen expressed on mature lymphocytes
    J. Immunol  145-  3924  1990  [Not refereed][Not invited]
  • DNA and Cell Biology  9-  (3)  213  -220  1990  [Not refereed][Not invited]
  • Natural killer cell activity in workers exposed to benzidine and B-naphthylamine.
    Brit. J. Indust. Med.  42-  338  1990  [Not refereed][Not invited]
  • Interleukin-7 promotes thymocyte proliferation and maintains immunocompetent thymocytes bearing αβ or γδ T cell receptors in vitro. Synergism with interleukin 2.
    J. Immunol  143-  2917  1989  [Not refereed][Not invited]
  • 皮膚血管炎(過敏性血管炎)
    神経症候群(]G0004[)(臨域別症候群シリーズ No.29)  29-  310  [Not refereed][Not invited]
  • Cutaneous leukocytoclastic angiitis(hypersensitivity vasculitis)
    29-  310  [Not refereed][Not invited]

Research Grants & Projects

  • 医学教育と試験・評価
    Date (from‐to) : 2009 -2011
  • Introduction of SEQ into medical examination
    Date (from‐to) : 2009 -2011
  • Th1/Th2バランスと自己免疫疾患
  • アポトーシスの異常と自己免疫疾患
  • T細胞の分化・増殖に関する研究
  • Th1/Th2 Balance in Autoimmune Diseases
  • Apoptotic Defects and Autoimmune Diseases
  • Study on T cell differentiation and proliferation


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.